Savara Inc. (NASDAQ:SVRA) Receives Average Recommendation of "Moderate Buy" from Analysts

Savara Inc. (NASDAQ:SVRA - Get Free Report) has received an average rating of "Moderate Buy" from the five ratings firms that are presently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $5.60.

Several equities research analysts have commented on the stock. Guggenheim reaffirmed a "buy" rating and issued a $8.00 price target (down from $9.00) on shares of Savara in a report on Wednesday, May 28th. HC Wainwright cut Savara from a "buy" rating to a "neutral" rating and dropped their target price for the company from $6.00 to $2.00 in a research report on Thursday, May 29th. Wells Fargo & Company dropped their price objective on Savara from $8.00 to $7.00 and set an "overweight" rating on the stock in a report on Wednesday, May 28th. Finally, Evercore ISI cut their price objective on Savara from $3.00 to $2.00 and set an "in-line" rating for the company in a research report on Wednesday, May 28th.

Insider Activity

In other Savara news, Director Richard J. Hawkins acquired 48,225 shares of the business's stock in a transaction that occurred on Friday, June 20th. The stock was purchased at an average cost of $2.04 per share, with a total value of $98,379.00. Following the transaction, the director owned 115,466 shares of the company's stock, valued at $235,550.64. This trade represents a 71.72% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 5.33% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Savara

A number of institutional investors have recently modified their holdings of SVRA. Altium Capital Management LLC raised its holdings in shares of Savara by 0.3% in the 4th quarter. Altium Capital Management LLC now owns 1,579,000 shares of the company's stock valued at $4,848,000 after purchasing an additional 4,000 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in Savara by 13.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 43,668 shares of the company's stock valued at $135,000 after buying an additional 5,236 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in Savara by 3.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 143,661 shares of the company's stock worth $441,000 after buying an additional 5,450 shares during the last quarter. Farther Finance Advisors LLC boosted its position in shares of Savara by 17.6% during the 2nd quarter. Farther Finance Advisors LLC now owns 38,001 shares of the company's stock worth $87,000 after acquiring an additional 5,687 shares in the last quarter. Finally, Barclays PLC boosted its position in shares of Savara by 2.5% during the 4th quarter. Barclays PLC now owns 236,705 shares of the company's stock worth $728,000 after acquiring an additional 5,700 shares in the last quarter. 87.93% of the stock is owned by institutional investors and hedge funds.

Savara Stock Performance

Shares of SVRA stock opened at $2.26 on Friday. The company has a debt-to-equity ratio of 0.20, a quick ratio of 14.91 and a current ratio of 14.91. The company has a market capitalization of $390.62 million, a price-to-earnings ratio of -4.71 and a beta of 0.31. Savara has a one year low of $1.89 and a one year high of $4.74. The company's 50-day moving average is $2.41 and its 200 day moving average is $2.70.

Savara (NASDAQ:SVRA - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.12) EPS for the quarter, meeting the consensus estimate of ($0.12). Sell-side analysts expect that Savara will post -0.45 EPS for the current fiscal year.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.